首页 >
法规速递
-
Document: Letter of intent for the submission of a worksharing procedure to the European Medicines Agency according to Article 65 of Regulation (EU) 2019/6-2025/9/17
2025-09-18查看详情 > -
Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments-2025/10/22
2025-10-24查看详情 > -
Document: European Medicines Agency post-authorisation procedural advice for users of the centralised procedure-2025/11/26
2025-11-27查看详情 > -
Page: Medicine shortages and availability issues: guidance for companies-2025/12/17
2025-12-18查看详情 > -
Document: Three-year work plan for the Quality Drafting Group (QDG) of the Committee on Herbal Medicinal Products (HMPC)-2026/2/3
2026-02-04查看详情 > -
Document: Agenda of the CVMP meeting 10-12 March 2026-2026/3/11
2026-03-12查看详情 > -
Page: PRIME: priority medicines-2026/4/9
2026-04-10查看详情 > -
Regulatory and procedural guideline: European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure: document with tracked changes (updated)-2022/12/21
2022-12-21查看详情 > -
国家药监局关于银黄含片等4种药品转换为非处方药的公告（2023年第93号）-2023/7/25
2023-07-28查看详情 > -
Page: Allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations - Scientific guideline-2024/2/23
2024-03-11查看详情 >
